^
4d
Trial completion
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
4d
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (clinicaltrials.gov)
P2, N=34, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Feb 2025 --> Jun 2025
Trial completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
melphalan • fludarabine IV
4d
New trial
|
CD47 (CD47 Molecule)
4d
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies (clinicaltrials.gov)
P=N/A, N=81, Completed, Ann & Robert H Lurie Children's Hospital of Chicago | Unknown status --> Completed | N=200 --> 81
Trial completion • Enrollment change
|
cyclophosphamide
4d
Trial completion • Trial completion date
|
dasatinib • imatinib
4d
The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis. (PubMed, Leuk Res)
SLC variants can be predictive signals of imatinib responses among CML; Asian patients should be paid attention during the treatment.
Retrospective data • Journal
|
SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • SLC22A1 (Solute Carrier Family 22 Member 1)
|
imatinib
6d
New P2 trial
|
Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV
6d
Enrollment open
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Iclusig (ponatinib) • Scemblix (asciminib)
6d
Effects of YAP Inhibitors and Activators on the Growth of Leukemia Cells. (PubMed, Anticancer Res)
YAP activators suppressed the growth of leukemia cells through induction of apoptosis. This suggested that YAP might function as a tumor suppressor in leukemia. SBP-3264 and XMU-MP-1 could be novel candidate molecular-targeted drugs for leukemia; however, further investigations are required.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NOTCH1 (Notch 1) • CASP3 (Caspase 3)
|
Visudyne (verteporfin)
8d
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
P2, N=61, Completed, City of Hope Medical Center | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Sep 2024
Trial completion • Trial completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
8d
HQP1351CC203: A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase (clinicaltrials.gov)
P2, N=144, Completed, Ascentage Pharma Group Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2024 | Trial primary completion date: Dec 2024 --> Aug 2024
Trial completion • Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
dasatinib • imatinib • Tasigna (nilotinib) • Nailike (olverembatinib) • Synribo (omacetaxine mepesuccinate) • hydroxyurea
8d
A multi-modal molecular characterization of the Philadelphia translocation featuring long read sequencing. (PubMed, Gene)
Using the Ph translocation as an example, long read sequencing is shown to be a promising alternative method to detect SV, revolutionizing detection of chromosomal translocation to a higher precision. A more comprehensive spectrum of SV can be resolved along with cytogenetic results, enabling precise diagnosis and personalized monitoring of haematological malignancies.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
9d
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent. (PubMed, Cell Biol Int)
This study compared responses of three commonly used CML cell lines (K562, LAMA84, KCL22) to five TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib) and a Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor commonly used in clinical settings. This comprehensive comparison provides valuable insights for refining preclinical models and enhancing translational relevance in CML research and treatment development. Understanding the diverse responses of CML cell lines to TKIs and STAMP inhibitor facilitates the selection of appropriate models for specific research questions, ultimately improving the accuracy and reliability of preclinical studies in CML.
Preclinical • Journal
|
ABL1 (ABL proto-oncogene 1)
|
ABL1 fusion
|
dasatinib • imatinib • Iclusig (ponatinib) • Tasigna (nilotinib) • Bosulif (bosutinib)
10d
mir-188-5p emerges as an oncomir to promote chronic myeloid leukemia via upregulation of BUB3 and SUMO2. (PubMed, Mol Biol Rep)
Our results suggest that miR-188-5p acts as an oncomiRNA in CML pathogenesis and may be a promising therapeutic target for CML.
Journal
|
MIR188 (MicroRNA 188)
11d
ASC4KIDS: Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia (clinicaltrials.gov)
P1/2, N=34, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Jun 2026 --> Jul 2025
Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Scemblix (asciminib)
11d
Ginsenoside-Rg5 Synergizes with Imatinib to Enhances the Anti-Chronic Myeloid Leukemia K562 Cell Activity through PI3K/AKT/mTOR Pathway (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
The combination of ginsenoside-Rg5 and imatinib can inhibit the proliferation of CML cells and induce apoptosis, and the mechanism may act through PI3K/AKT/mTOR signaling pathways.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
imatinib
12d
ASC4OPT: Asciminib Treatment Optimization in ≥ 3rd Line CML-CP. (clinicaltrials.gov)
P3, N=169, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Apr 2026 --> Mar 2024
Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Scemblix (asciminib)
13d
Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia. (PubMed, Int J Hematol)
This study revealed that bosutinib-induced elevation of serum creatinine, which was more pronounced in patients with the SLC22A2 808G/G genotype, does not indicate chronic kidney disease, but rather is simply a laboratory abnormality. If bosutinib-induced chronic kidney disease is suspected, renal function should be assessed by urinalysis and cystatin C levels to differentiate from simple elevation of serum creatinine.
Journal
|
SLC22A2 (Solute Carrier Family 22 Member 2)
|
Bosulif (bosutinib)
13d
Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment. (PubMed, Curr Oncol)
Switching to second-line dasatinib treatment successfully overcame asciminib resistance and helped to achieve a deep molecular response. In case of treatment failures caused by single asciminib-specific point mutations, dasatinib therapy is a feasible choice.
Journal
|
ABL1 (ABL proto-oncogene 1)
|
dasatinib • Scemblix (asciminib)
14d
MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Bax, Puma and Noxa expression levels in imatinib‑resistant chronic myeloid leukemia cells. (PubMed, Biomed Rep)
NSC-66811 and Nutlin-3, MDM2 inhibitors, increased the percentage of Annexin-positive cells in K562/IR cells by 43 and 62% at concentrations of 10 and 25 µM, respectively. Additionally, pifithrin-α, a p53 inhibitor, suppressed MDM2 inhibitor-induced cell death in K562/IR cells. Overall, the findings of the present study highlight the therapeutic potential of MDM2 inhibitors for imatinib-resistant CML.
Journal
|
ABL1 (ABL proto-oncogene 1) • MDM2 (E3 ubiquitin protein ligase) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ANXA5 (Annexin A5) • BBC3 (BCL2 Binding Component 3) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
|
imatinib • Nutlin-3
15d
TGRX-678-1001: TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients (clinicaltrials.gov)
P1, N=90, Active, not recruiting, Shenzhen TargetRx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Sep 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
Enrollment closed • Trial completion date • Trial primary completion date
|
TGRX-678
18d
TGRX-678-1002: TGRX-678 Phase I Oral Pharmacokinetic Study (clinicaltrials.gov)
P1, N=72, Active, not recruiting, Shenzhen TargetRx, Inc. | Not yet recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Jul 2025
Enrollment closed • Trial completion date
|
TGRX-678
18d
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients (clinicaltrials.gov)
P2, N=40, Recruiting, Shenzhen TargetRx, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Dec 2027 --> Apr 2028
Enrollment open • Trial completion date
|
TGRX-678
18d
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov)
P2, N=40, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Feb 2025
Enrollment open • Trial initiation date
|
Scemblix (asciminib)
18d
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts W/Chronic Myeloid Leukemia (clinicaltrials.gov)
P=N/A, N=75, Recruiting, University of California, Irvine | Trial primary completion date: Dec 2024 --> Dec 2025
Trial primary completion date
18d
Inactivation of necroptosis-promoting protein MLKL creates a therapeutic vulnerability in colorectal cancer cells. (PubMed, Cell Death Dis)
MLKL inactivation reduces such autophagy and renders the cells sensitive to autophagy inhibitors, such as homoharringtonine. Hence, MLKL inhibition creates a therapeutic vulnerability that could be utilized for CRC treatment.
Journal
|
VPS37A (Vacuolar protein sorting-associated protein 37A) • MLKL (Mixed Lineage Kinase Domain Like Pseudokinase)
|
Synribo (omacetaxine mepesuccinate)
19d
Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity. (PubMed, Front Immunol)
Interestingly, STING expression was negatively correlated with TIDE biomarkers in AML, suggesting that AML patients with a high STING expression level may benefit from immunologic treatment. Our findings contribute a molecular characterization of STING across hematological malignancies, facilitating the development of individualized prognosis and treatment strategies.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • STING (stimulator of interferon response cGAMP interactor 1) • IFNA1 (Interferon Alpha 1)
20d
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors (clinicaltrials.gov)
P2, N=24, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=41 --> 24 | Trial completion date: Dec 2026 --> Feb 2026 | Trial primary completion date: Feb 2026 --> Feb 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Jakafi (ruxolitinib)
20d
Trial completion date
|
Chr del(5q)
|
etoposide IV • busulfan • cyclosporine
20d
Trial completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
Triplex (CMV-MVA vaccine)
22d
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients. (PubMed, Eur J Haematol)
Our study indicates that in patients with a low BCR::ABL1 digital PCR result, a total TKI treatment duration of six or more years remains associated with a lower MolR rate and should generally be pursued. In patients treated for more than 6 years, BCR::ABL1 digital PCR was capable to identify stop candidates with a higher probability of TFR success.
Journal
|
ABL1 (ABL proto-oncogene 1)
23d
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms (clinicaltrials.gov)
P1, N=25, Recruiting, Mayo Clinic | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
Trial completion date • Trial primary completion date
|
onvansertib (PCM-075)
23d
CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells. (PubMed, Cell Death Discov)
Imatinib mesylate (IM) and other BCR-ABL tyrosine kinase inhibitors (BCR-ABLi) are the mainstay of chronic myelogenous leukemia (CML) treatment...Dissecting the effects of pharmacological CDK8/19 inhibition on CML survival in response to BCR-ABLi, we found that a selective, non-toxic CDK8/19 inhibitor (CDK8/19i) Senexin B (SenB) and other CDK8/19i sensitized K562 cells to different BCR-ABLi via attenuation of cell cycle arrest...In contrast, IM-treated BCR-ABL-positive KU812 CML cells, which did not induce p27Kip1, readily died regardless of SenB treatment. Thus, CDK8/19i prevent the quiescence-mediated escape from BCR-ABLi-induced apoptosis, suggesting a strategy for avoiding the CML relapse.
Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CASP9 (Caspase 9) • ANXA5 (Annexin A5)
|
imatinib • Senexin B
24d
Pelvic Hematoma Revealing Chronic Myeloid Leukemia: Case Report of Two Patients. (PubMed, Cardiovasc Hematol Disord Drug Targets)
Initial manifestation of CML with pelvic hematoma is uncommon and should undergo aspiration or drainage to avoid organization of hematoma and compressive symptoms locally.
Journal
|
ABL1 (ABL proto-oncogene 1)
25d
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells. (PubMed, Exp Hematol Oncol)
This study demonstrates that CD26 CAR-M effectively targets and phagocytizes CD26-positive CML cells, implying that targeting CD26 with CAR-M could be a viable method for eradicating CML-LSCs. Furthermore, our discoveries illuminate the potential application of CAR-M in treating hematological malignancies.
Journal
|
GLI2 (GLI Family Zinc Finger 2) • DPP4 (Dipeptidyl Peptidase 4)
26d
Trial completion
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Scemblix (asciminib)
26d
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis. (PubMed, Cell Mol Immunol)
Finally, by examining whether NCPs and all other CD66b+ neutrophil precursors are altered in representative hematological malignancies, we found that, in patients with chronic-phase chronic myeloid leukemia (CP-CML), but not with systemic mastocytosis (SM), there is an increased frequency of BM NCP4s, NCP6s, and all downstream CD45RA-negative neutrophil progenitors, suggesting their expansion in CML pathogenesis. Taken together, our data advance our knowledge of human neutropoiesis.
Journal
|
CEACAM8 (CEA Cell Adhesion Molecule 8)
27d
Asciminib in the treatment of chronic myeloid leukemia in chronic phase. (PubMed, Future Oncol)
Asciminib has shown significant cytogenetic and molecular responses in heavily pretreated patients, those previously exposed to ponatinib, and treatment-naïve individuals, attributed to its pharmacological selectivity and generally favorable safety profile. This review provides an in-depth analysis of the preclinical and clinical evidence supporting the use of asciminib, synthesizing findings from a targeted literature search of PubMed and Web of Science. Our discussion integrates insights into its mechanism of action, clinical efficacy, safety, resistance patterns, and future directions.
Review • Journal
|
ABL1 (ABL proto-oncogene 1)
|
Iclusig (ponatinib) • Scemblix (asciminib)
27d
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders (clinicaltrials.gov)
P2, N=33, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026
Trial completion date • Trial primary completion date
|
melphalan
28d
2-Amino-4,6-diarylpyrimidines as potential chronic myeloid leukemia cell inhibitors targeting anti-ABL1 kinase: microwave-assisted synthesis, biological evaluation, molecular docking, and dynamics studies. (PubMed, RSC Adv)
Moreover, the stability of these enzyme-ligand complexes was confirmed using molecular dynamics simulations. These findings suggested that compounds 1e and 1g can be considered promising cancer treatment agents.
Journal
|
ABL1 (ABL proto-oncogene 1)